APR 01, 2015 08:25 AM PDT

How Immune Cells Facilitate the Spread of Breast Cancer

The body's immune system fights disease, infections and even cancer, acting like foot soldiers to protect against invaders and dissenters. But it turns out the immune system has traitors among its ranks. Dr. Karin de Visser and her team at the Netherlands Cancer Institute discovered that certain immune cells are persuaded by breast tumors to facilitate the spread of cancer cells. Their findings are published advanced online on March 30 in the journal Nature.
A few years ago, it was reported that breast cancer patients with a high number of immune cells called neutrophils in their blood are at increased risk of developing metastases.
In Western countries about one in eight women will develop breast cancer. Of the women who die of this disease, 90 percent dies because the cancer has spread to other parts of their body and formed metastases. For this reason, cancer researchers are trying to understand how the process of metastasis occurs. A few years ago, it was reported that breast cancer patients with a high number of immune cells called neutrophils in their blood are at increased risk of developing metastases. Immune cells are supposed to protect our body. So why are high neutrophil levels linked to worse outcome in women with breast cancer?

Dr. Karin de Visser, group leader at the Netherlands Cancer Institute, and her team discovered that certain types of breast tumors cause a domino effect of reactions within the immune system. The tumor sends out signaling molecules that through a number of steps cause the immune system to produce lots of neutrophils. This normally happens as part of an inflammatory reaction, but the neutrophils that are activated by the tumor behave differently. It turns out they are able to block the actions of other immune cells, called T cells. T cells are the cells that can (sometimes) recognize and kill cancer cells.

De Visser and her team went on to discover that a signaling protein called interleukin 17 (or IL17) is important for this process. "We saw in our experiments that IL17 is crucial for the increased production of neutrophils", says De Visser. "And not only that, it turns out that this is also the molecule that changes the behavior of the neutrophils, causing them to become T cell inhibitory."

The first author of the paper in Nature, postdoctoral researcher Seth Coffelt, showed the importance of the IL17-neutrophil pathway by inhibiting this pathway in a mouse model that mimics human breast cancer metastasis. When neutrophils were inhibited, the animals developed much less metastases than animals from the control group, in which the IL17-neutrophil route was not inhibited. "What's notable is that blocking the IL17-neutrophil route prevented the development of metastases, but did not affect the primary tumor," De Visser comments. "So this could be a promising strategy to prevent the tumor from spreading."

Since neutrophils are important to protect us from infections, drugs that inhibit neutrophils would make patients susceptible to all kinds of infections. Inhibition of IL17 might be a safer strategy. In fact, drugs that do so already exist. Anti-IL17 drugs are currently being tested in clinical trials as a treatment for inflammatory diseases, like psoriasis and rheumatism. Last month, the first anti-IL17 based therapy for psoriasis patients was approved by the U.S. Federal Drug Administration (FDA). "It would be very interesting to investigate whether these already existing drugs are beneficial for breast cancer patients. It may be possible to turn these traitors of the immune system back towards the good side and prevent their ability to promote breast cancer metastasis," De Visser says.

Source: Netherlands Cancer Institute
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 05, 2018
Cancer
JUN 05, 2018
Clinical Trial Evaluates Precision Medicine Approaches for Common and Rare Cancers
The NCI-MATCH Phase II Clinical Trial is evaluating results of cancer treatments administered based on genetic profiles determined through molecular diagnostic testing....
JUN 13, 2018
Cancer
JUN 13, 2018
Tailored vaccine boosts survival for some brain cancer patients
In a new multicenter clinical trial, a personalized vaccine improved the survival rates of some people with the deadly brain cancer glioblastoma. Currently...
JUN 27, 2018
Cancer
JUN 27, 2018
Engineered Poliovirus in Clinical Trials for Glioblastoma
Glioblastoma is a very difficult cancer to treat; researchers look to an engineered poliovirus for novel targeted approach for grade IV patients....
JUN 27, 2018
Infographics
JUN 27, 2018
The Role of Biomarkers In Modern Medicine
A biomarker (short for biological marker) is a measurable indicator of some biological state or condition. The biomarker can be measured objectively and consistently. Biomarkers play signific...
JUL 18, 2018
Immunology
JUL 18, 2018
Immunotherapy Increases Survival of Melanoma Brain Metastases Patients
Use of Checkpoint Blockade Immunotherapy increases survival rates in Melanoma Brain Metastases patients, with a 4-year survival rate increase from 11.1% to 28.1%...
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
Loading Comments...